GBR401 has been developed completely in-house by Glenmark‘s Biologics Research Centre located in Switzerland, using an advanced technology.
GBR 401 targets lymphomas, leukemia’s of B-cell origin and inflammatory disorders such as rheumatoid arthritis.
GBR 401 showed strong anti-tumor potency and anti-proliferative apoptotic activity in several in-vitro and in-vivo studies.
Glenmark president Michael Buschle said targeting CD19 is a promising approach to treat B-cell malignancies.
Glenmark plans to file for Phase I trials in the quarter of 2011-12.